Like any kid growing up at a time when the notion of adolescent martial arts-practicing humanoid amphibians did not seem weird at all, I was pretty fascinated by ninjas. This obsession manifested many ...
Regenxbio's RGX-121 gene therapy for Hunter syndrome is the main catalyst, with FDA approval targeted for February 2026. Recent clinical data shows RGX-121 can address neurological decline, a major ...
Primary endpoint of CSF HS D2S6 reduction at week 16 met; strong correlation to neurodevelopmental outcomes at 1 year, supporting HS D2S6 as surrogate biomarker reasonably likely to predict clinical ...
Knives are everywhere. Everybody uses them, everybody needs them, and in Portland there’s no better place to get them. The Portland area is saturated with blades, from striking kitchen knives made ...
RGX-121 is being developed to treat patients with MPS II, also known as Hunter Syndrome. Stifel has maintained its Buy rating and $40.00 price target on Regenxbio stock following the announcement. The ...
The company expects to complete pivotal enrollment for RGX-202 in October 2025 and report topline data in early 2026, with a BLA submission targeted for mid-2026 and a commercial launch potential by ...
RGX helps businesses recycle electronics locally, cutting costs and emissions while boosting ROI. A smarter way to handle e-waste year-round. Too often, recycling comes down to cost or convenience. We ...
ROCKVILLE, Md., Jan. 30, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced data from its RGX-121 (clemidsogene lanparvovec) program for the treatment of mucopolysaccharidosis type II ...
Oh yes, and there are also the usual slots – three, in this case – for optional vials of glow-in-the-dark tritium. Assuming the WingSpan multitool reaches production, a pledge of US$139 will get you ...
(RTTNews) - REGENXBIO Inc. (RGNX) and Nippon Shinyaku announced a strategic partnership for the development and commercialization of RGX-121 for the treatment of Mucopolysaccharidosis II, also known ...
Pivotal data evaluating the safety and efficacy of the subretinal delivery of ABBV-RGX-314 in patients with wet age-related macular degeneration (wet AMD) are expected in 2026 AbbVie and REGENXBIO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback